Previous 10 | Next 10 |
C4 Therapeutics Inc. (CCCC) is expected to report $-0.65 for Q3 2023
2023-11-01 10:14:30 ET More on C4 Therapeutics C4 Therapeutics: Way Too Long A Wait For This One Seeking Alpha’s Quant Rating on C4 Therapeutics Historical earnings data for C4 Therapeutics Financial information for C4 Therapeutics For further ...
Portfolio Decision to Prioritize Ongoing Phase 1/2 Trials of CFT7455, an IKZF1/3 Degrader, and CFT1946, a BRAF V600 Degrader CFT8634, a BRD9 Degrader, Will Not Advance in Synovial Sarcoma and SMARCB1-Null Tumors Due to Insufficient Single Agent Efficacy, Despite High Levels of BRD9 Degr...
2023-10-24 10:01:59 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in For further details see: American Well Corporation, ImmunityBio amon...
CFT8634 Phase 1 Dose Escalation Data to be Presented at the Connective Tissue Oncology Society Annual Meeting on November 2, 2023 CFT7455 Monotherapy Phase 1 Dose Escalation Complete in Relapsed/Refractory Multiple Myeloma; Data to be Presented at a Company-Sponsored Event on December 1...
2023-09-21 03:33:19 ET Summary C4 Therapeutics is a biotech company working on novel cancer treatments, but it is still in early stages and not recommended for investment. Their pipeline includes protein degraders for multiple myeloma, lymphomas, synovial sarcoma, and EGFR mutatio...
2023-09-18 06:42:01 ET More on ImmunoGen Seeking Alpha’s Quant Rating on ImmunoGen Historical earnings data for ImmunoGen Financial information for ImmunoGen ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty? Immun...
2023-09-05 16:12:58 ET More on C4 Therapeutics Seeking Alpha’s Quant Rating on C4 Therapeutics Historical earnings data for C4 Therapeutics Financial information for C4 Therapeutics C4 Therapeutics gains as FDA clears trial application for lung cancer ...
WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, tod...
2023-08-08 08:04:24 ET C4 Therapeutics press release ( NASDAQ: CCCC ): Q2 GAAP EPS of -$0.73. Revenue of $2.7M (-80.4% Y/Y). For further details see: C4 Therapeutics GAAP EPS of -$0.73, revenue of $2.7M
News, Short Squeeze, Breakout and More Instantly...
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing...
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Prote...
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform t...